What IP is behind the self-amplifying mRNA vaccine platform developed by Arcturus Therapeutics?
…achievement of certain development and commercial milestones along with royalties and profit sharing on future product sales. Accordingly, the intellectual property of Arcturus Therapeutics on saRNA technology is important to better understand the technology developed by the company. Arcturus Therapeutics’ patent portfolio comprises 46 patent families, and the company owns…